Table 1.

Hazard ratio (HR) of meningioma in patients diagnosed with prostatic hyperplasia and prostate carcinoma, according to the use-, and time since first use of male hormone-interfering drugs compared to never users

Time since first use	Risk time (person-years)	Meningioma cases	HR	95 % CI
Never use	1,351,000	339	1	Reference
Ever use	378,000	105	1.02	(0.82–1.27)
0–1 years	76,000	19	0.97	(0.61–1.55)
2–4 years	103,000	27	1.01	(0.68–1.50)
5+ years	199,000	59	1.04	(0.79–1.39)

CI, confidence interval; HR, hazard ratio.